Cargando…

Therapeutic efficacy against Mycobacterium tuberculosis using ID93 and liposomal adjuvant formulations

Mycobacterium tuberculosis (M.tb) has led to approximately 1.3 million deaths globally in 2020 according to the World Health Organization (WHO). More effective treatments are therefore required to prevent the transmission of M.tb. Although Bacille Calmette–Guérin (BCG), a prophylactic vaccine agains...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baldwin, Susan L., Reese, Valerie A., Larsen, Sasha E., Pecor, Tiffany, Brown, Bryan P., Granger, Brian, Podell, Brendan K., Fox, Christopher B., Reed, Steven G., Coler, Rhea N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Microbiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459154/ https://www.ncbi.nlm.nih.gov/pubmed/36090093 http://dx.doi.org/10.3389/fmicb.2022.935444

Ejemplares similares

Prophylactic efficacy against Mycobacterium tuberculosis using ID93 and lipid-based adjuvant formulations in the mouse model
por: Baldwin, Susan L., et al.
Publicado: (2021)

Enhanced Anti-Mycobacterium tuberculosis Immunity over Time with Combined Drug and Immunotherapy Treatment
por: Larsen, Sasha E., et al.
Publicado: (2018)

Subunit vaccine protects against a clinical isolate of Mycobacterium avium in wild type and immunocompromised mouse models
por: Larsen, Sasha E., et al.
Publicado: (2021)

A Dual TLR Agonist Adjuvant Enhances the Immunogenicity and Protective Efficacy of the Tuberculosis Vaccine Antigen ID93
por: Orr, Mark T., et al.
Publicado: (2014)

An RNA-Based Vaccine Platform for Use against Mycobacterium tuberculosis
por: Larsen, Sasha E., et al.
Publicado: (2023)

Long-term protective efficacy with a BCG-prime ID93/GLA-SE boost regimen against the hyper-virulent Mycobacterium tuberculosis strain K in a mouse model
por: Kwon, Kee Woong, et al.
Publicado: (2019)

Characterizing in vivo loss of virulence of an HN878 Mycobacterium tuberculosis isolate from a genetic duplication event
por: Berube, Bryan J., et al.
Publicado: (2022)

Safety and Immunogenicity of the ID93 + GLA-SE Tuberculosis Vaccine in BCG-Vaccinated Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial
por: Choi, Yu Hwa, et al.
Publicado: (2023)

The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial
por: Coler, Rhea N., et al.
Publicado: (2018)

It Takes a Village: The Multifaceted Immune Response to Mycobacterium tuberculosis Infection and Vaccine-Induced Immunity
por: Larsen, Sasha E., et al.
Publicado: (2022)

Improved Immune Responses in Young and Aged Mice with Adjuvanted Vaccines against H1N1 Influenza Infection
por: Baldwin, Susan L., et al.
Publicado: (2018)

Tuberculosis vaccines update: Is an RNA-based vaccine feasible for tuberculosis?
por: Larsen, Sasha E., et al.
Publicado: (2023)

Stressed stability and protective efficacy of lead lyophilized formulations of ID93+GLA-SE tuberculosis vaccine
por: Archer, Michelle C., et al.
Publicado: (2023)

The complexities and challenges of preventing and treating nontuberculous mycobacterial diseases
por: Baldwin, Susan L., et al.
Publicado: (2019)

A Formulated TLR7/8 Agonist is a Flexible, Highly Potent and Effective Adjuvant for Pandemic Influenza Vaccines
por: Van Hoeven, Neal, et al.
Publicado: (2017)

Adjuvanted pandemic influenza vaccine: variation of emulsion components affects stability, antigen structure, and vaccine efficacy
por: Fox, Christopher B., et al.
Publicado: (2012)

A Novel Synthetic TLR-4 Agonist Adjuvant Increases the Protective Response to a Clinical-Stage West Nile Virus Vaccine Antigen in Multiple Formulations
por: Van Hoeven, Neal, et al.
Publicado: (2016)

Mycobacterium abscessus: It’s Complex
por: Abdelaal, Hazem F. M., et al.
Publicado: (2022)

Development and Characterization of Synthetic Glucopyranosyl Lipid Adjuvant System as a Vaccine Adjuvant
por: Coler, Rhea N., et al.
Publicado: (2011)

Qualification of ELISA and neutralization methodologies to measure SARS-CoV-2 humoral immunity using human clinical samples
por: Larsen, Sasha E., et al.
Publicado: (2021)

Qualification of ELISA and neutralization methodologies to measure SARS-CoV-2 humoral immunity using human clinical samples
por: Larsen, Sasha E., et al.
Publicado: (2021)

Cryogenic transmission electron microscopy of recombinant tuberculosis vaccine antigen with anionic liposomes reveals formation of flattened liposomes
por: Fox, Christopher B, et al.
Publicado: (2014)

Controlled Covalent Conjugation of a Tuberculosis Subunit Antigen (ID93) to Liposome Improved In Vitro Th1-Type Cytokine Recall Responses in Human Whole Blood
por: Adeagbo, Babatunde Ayodeji, et al.
Publicado: (2020)

A combination of TLR-4 agonist and saponin adjuvants increases antibody diversity and protective efficacy of a recombinant West Nile Virus antigen
por: Van Hoeven, Neal, et al.
Publicado: (2018)

Preparation Strategies of the Anti-Mycobacterial Drug Bedaquiline for Intrapulmonary Routes of Administration
por: Maloney, Sara E., et al.
Publicado: (2023)

Liposome-Based Adjuvants for Subunit Vaccines: Formulation Strategies for Subunit Antigens and Immunostimulators
por: Tandrup Schmidt, Signe, et al.
Publicado: (2016)

Spike-specific T cells are enriched in breastmilk following SARS-CoV-2 mRNA vaccination
por: Armistead, Blair, et al.
Publicado: (2022)

Overcoming the Neonatal Limitations of Inducing Germinal Centers through Liposome-Based Adjuvants Including C-Type Lectin Agonists Trehalose Dibehenate or Curdlan
por: Vono, Maria, et al.
Publicado: (2018)

Safety and immunogenicity of a thermostable ID93 + GLA-SE tuberculosis vaccine candidate in healthy adults
por: Sagawa, Zachary K., et al.
Publicado: (2023)

A Synthetic Adjuvant to Enhance and Expand Immune Responses to Influenza Vaccines
por: Coler, Rhea N., et al.
Publicado: (2010)

Spike-specific T cells are enriched in breastmilk following SARS-CoV-2 mRNA vaccination
por: Armistead, Blair, et al.
Publicado: (2023)

The TLR4 Agonist Vaccine Adjuvant, GLA-SE, Requires Canonical and Atypical Mechanisms of Action for T(H)1 Induction
por: Cauwelaert, Natasha Dubois, et al.
Publicado: (2016)

Abstract 1647: Quantification of functional antibody titers in a mouse model of SARS-CoV-2 infection
por: Hernandez, Dulce, et al.
Publicado: (2023)

Liposomal formulation of Gp41 derivate with adjuvant MPLA: vaccine design, immunogenicity in animals and safety in humans
por: Katinger, D, et al.
Publicado: (2012)

Host-directed therapy targeting the Mycobacterium tuberculosis granuloma: a review
por: Kiran, Dilara, et al.
Publicado: (2015)

Pharmacokinetic Analyses of Liposomal and Non-Liposomal Multivitamin/Mineral Formulations
por: Ko, Joungbo, et al.
Publicado: (2023)

Injection Vaccines Formulated with Nucleotide, Liposomal or Mineral Oil Adjuvants Induce Distinct Differences in Immunogenicity in Rainbow Trout
por: Rømer Villumsen, Kasper, et al.
Publicado: (2020)

Recombinant polymorphic membrane protein D in combination with a novel, second-generation lipid adjuvant protects against intra-vaginal Chlamydia trachomatis infection in mice
por: Paes, Wayne, et al.
Publicado: (2016)

Formulation and Evaluation of Celastrol-Loaded Liposomes
por: Song, Jie, et al.
Publicado: (2011)

Development and characterization of liposomal formulation of bortezomib
por: Deshantri, Anil K., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_3igp39ms6m3k3vks4nd2d0t36v